Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21

Core Insights - Axsome Therapeutics, Inc. is hosting its Frontiers in Brain Health R&D Day on July 21, 2025, to showcase its innovative late-stage CNS pipeline [1][2] - The event will feature discussions from physician key opinion leaders on current indications in neurology and psychiatry, along with an overview of clinical development programs by Axsome's management team [2] Company Overview - Axsome Therapeutics is a biopharmaceutical company focused on treating central nervous system (CNS) disorders, with a portfolio that includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine [4] - The company aims to address significant gaps in care by developing differentiated products that lead to meaningful advancements in patient outcomes, impacting over 150 million people in the United States [4]